Emergent BioSolutions/$EBS
1D1W1MYTD1Y5YMAX
About Emergent BioSolutions
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
- Ticker
- $EBS
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 900
- Headquarters
- Gaithersburg, United States
- Website
- www.emergentbiosolutions.com
EBS Metrics
BasicAdvanced
$303M
-
-$3.39
2.36
-
Price and volume
Market cap
$303M
Beta
2.36
52-week high
$14.06
52-week low
$4.36
Average daily volume
1.2M
Financial strength
Current ratio
5.423
Quick ratio
2.685
Long term debt to equity
171.851
Total debt to equity
172.291
Interest coverage (TTM)
2.76%
Profitability
EBITDA (TTM)
232.1
Gross margin (TTM)
49.39%
Net profit margin (TTM)
-22.95%
Operating margin (TTM)
18.20%
Effective tax rate (TTM)
-21.10%
Revenue per employee (TTM)
$860,000
Management effectiveness
Return on assets (TTM)
6.93%
Return on equity (TTM)
-40.29%
Valuation
Price to revenue (TTM)
0.401
Price to book
0.89
Price to tangible book (TTM)
3.81
Price to free cash flow (TTM)
8.69
Free cash flow yield (TTM)
11.51%
Free cash flow per share (TTM)
0.68
Growth
Revenue change (TTM)
-9.56%
Earnings per share change (TTM)
-234.01%
3-year revenue growth (CAGR)
-10.44%
10-year revenue growth (CAGR)
4.16%
3-year earnings per share growth (CAGR)
-34.39%
10-year earnings per share growth (CAGR)
9.38%
What the Analysts think about EBS
Analyst ratings (Buy, Hold, Sell) for Emergent BioSolutions stock.
EBS Financial Performance
Revenues and expenses
EBS Earnings Performance
Company profitability
EBS News
AllArticlesVideos
Emergent BioSolutions Inc. (EBS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Business Wire2 weeks ago
Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Business Wire2 weeks ago
EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.